The FDA enforcement report lists an ongoing Class II recall, dated 9 September 2026, of vancomycin injection 1 g in 200 mL sodium chloride in single-dose containers from Baxter Healthcare. The stated reason is deviations from current good manufacturing practice.
A Class II recall indicates the FDA considers that use may cause temporary or medically reversible harm, or that serious harm is unlikely. The notice describes no specific clinical problem. Whether affected lots reached India is not stated.
- The recall concerns one premixed vancomycin product, not vancomycin as a drug.
- Hospital pharmacies holding imported premixed vancomycin should check lot numbers against the FDA notice.
- No clinical harm is described, and patients already treated need no action.
- Reconstituted vancomycin from vials is not affected by this notice.
Why it matters
Premixed vancomycin is used for empirical sepsis cover, so a supply gap needs a planned alternative.
Don't overread it
A manufacturing-practice recall is not a finding that the drug is unsafe.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free